105.6 million voting rights were listed for Cellectis as of Oct. 31.
Cellectis reported 100.7 million shares and 105.6 million voting rights on Euronext Growth as of Oct. 31, according to a regulatory filing. The company provided contact details for media and investor relations.
How this was made
The 30-second read
Why it matters
The disclosed voting rights update informs shareholders of the current equity base, which can affect per-share metrics and dilution expectations.
Market read
A routine capital structure filing with modest trading relevance.
What to watch
Potential future equity offerings or conversions could further affect dilution.
Background
Cellectis is a French gene-editing biotech listed on Euronext Paris.
Market effects
Minor impact on biotech sector valuations due to updated share count.
Limited to French market where Cellectis trades.
Low global relevance.
Counterpoint
Investors may view the higher voting rights as a sign of upcoming financing or strategic moves.
Key entities
- CompanyCellectis
Gene-editing biotech firm.


